Filing Flows › BridgeBio Pharma (BBIO) › R&D spending
BridgeBio Pharma (BBIO) R&D spending by quarter
BridgeBio Pharma's R&D spending was $144M in Q3 2026 (third quarter 2026), -4% from Q2 2026. Over the last 7 quarters it ranged from $111M (Q2 2025) to $149M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $144M | -4% | +27% |
| Q2 2026 | $149M | +18% | +34% |
| Q1 2026 | $127M | +9% | +14% |
| Q4 2025 | $116M | +3% | — |
| Q3 2025 | $113M | +1% | — |
| Q2 2025 | $111M | -0.2% | — |
| Q1 2025 | $111M | — | — |
Q3 2026 at a glance
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is BridgeBio Pharma's R&D spending?
BridgeBio Pharma's R&D spending was $144M in Q3 2026 (third quarter 2026), -4% from Q2 2026.
How has BridgeBio Pharma's R&D spending changed?
Over the last 7 quarters it ranged from $111M (Q2 2025) to $149M (Q2 2026).